JMD Association for Molecular Pathology 2008 Annual Meeting
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, I.-J.
Right arrow Articles by Park, J.-G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kim, I.-J.
Right arrow Articles by Park, J.-G.
JMD 2007, Vol. 9, No. 1
Copyright © 2007 American Society for Investigative Pathology & Association for Molecular Pathology

Development and Applications of a BRAF Oligonucleotide Microarray

Il-Jin Kim*{dagger}, Hio Chung Kang*{dagger}, Sang Geun Jang*, Sun-A Ahn*, Hyun-Ju Yoon* and Jae-Gahb Park*{dagger}

From the Laboratory of Cell Biology, * Cancer Research Institute and Cancer Research Center, Seoul National University, Seoul, Korea; and the Research Institute and Hospital, {dagger} National Cancer Center, Goyang, Gyeonggi, Korea

We herein describe the development of a sensitive microarray hybridization method called competitive DNA hybridization (CDH) and its use for analysis of BRAF somatic mutations. These mutations have been identified in many human cancers, and fast, reliable BRAF mutation detection may one day facilitate directed therapy of BRAF-mutated tumors. Our fast, reliable mutation detection by CDH is based on the principle that competition among multiple fluorescent-labeled samples for binding to shared wild-type sequences should reduce nonspecific results and increase the positive signals of unshared mutated sequences. The positive signals can then be discriminated based on the labeling of each sample (ie, with Cy3, Cy5, or Alexa-594). For testing of this method, we developed a BRAF oligonucleotide microarray containing 65 mutation types (more than 95% of the known BRAF mutations) and validated this microarray with 20 colorectal cancer tissues/cancer cell lines with BRAF mutations and 60 BRAF-negative samples. In sum, we were able to screen up to nine cancer samples on a single BRAF microarray (three per CDH on three regions per slide), indicating that this method may dramatically decrease the experimental time, cost, and effort of mutation detection in BRAF and other genes amenable to microarray analysis.




This article has been cited by other articles:


Home page
 Appl. Environ. Microbiol.Home page
Z. He and J. Zhou
Empirical Evaluation of a New Method for Calculating Signal-to-Noise Ratio for Microarray Data Analysis
Appl. Envir. Microbiol., May 15, 2008; 74(10): 2957 - 2966.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society for Investigative Pathology and the Association for Molecular Pathology.